Cite
Johnson B, Loree JM, Jacome AA, et al. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00102.
Johnson, B., Loree, J. M., Jacome, A. A., Mendis, S., Syed, M., Morris Ii, V. K., Parseghian, C. M., Dasari, A., Pant, S., Raymond, V. M., Vilar, E., Overman, M., Kee, B., Eng, C., Raghav, K., & Kopetz, S. (2019). Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00102
Johnson, Benny, et al. "Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00102
Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019 Aug 05;3. doi: 10.1200/PO.19.00102. eCollection 2019. PMID: 32914034; PMCID: PMC7446507.
Copy
Download .nbib